Low-dose aspirin, rejection, and thrombosis: Is it the Wonder Drug® of liver transplantation?
- PMID: 35959844
- DOI: 10.1002/lt.26558
Low-dose aspirin, rejection, and thrombosis: Is it the Wonder Drug® of liver transplantation?
Comment on
-
Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation.Liver Transpl. 2022 Dec;28(12):1888-1898. doi: 10.1002/lt.26534. Epub 2022 Aug 5. Liver Transpl. 2022. PMID: 35735232 Free PMC article.
References
-
- Oberkofler CE, Raptis DA, Mueller PC, Sousa Da Silva RX, Lehmann K, Ito T, et al. Low‐dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation. Liver Transpl. 2022;28:1888–98.
-
- Zhu J, Gao B. Simvastatin combined with aspirin increases the survival time of heart allograft by activating CD4(+)CD25(+) Treg cells and enhancing vascular endothelial cell protection. Cardiovasc Pathol. 2015;24:173–8.
-
- Vassalli G. Dendritic cell‐based approaches for therapeutic immune regulation in solid‐organ transplantation. J Transplant. 2013;2013:761429.
-
- Zhang X, Chang A, Zou Y, Xu H, Cui J, Chen Z, et al. Aspirin attenuates cardiac allograft rejection by inhibiting the maturation of dendritic cells via the NF‐κB signaling pathway. Front Pharmacol. 2021;12:706748.
-
- Bergmark BA, Zelniker TA, Kim M, Mehra MR, Stewart GC, Page DS, et al. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. Clin Transplant. 2021;35:e14424.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
